Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 36NETWORK 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 3216Carcinoma, Non-Small-Cell Lung 2729Breast Neoplasms 2551Colorectal Neoplasms 1463Prostatic Neoplasms 1307Neoplasm Metastasis 1301Multiple Myeloma 1112Melanoma 1103Ovarian Neoplasms 1006Lung Neoplasms 945Recurrence 924Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 833Lymphoma, Non-Hodgkin 767Lymphoma 713Stomach Neoplasms 692Carcinoma, Renal Cell 660Carcinoma, Hepatocellular 647Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 550Lymphoma, Follicular 515Head and Neck Neoplasms 490Glioblastoma 473Small Cell Lung Carcinoma 447Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 436Advanced Solid Tumors 432Leukemia 426Uterine Cervical Neoplasms 420Urinary Bladder Neoplasms 405

Interventions

N-((1-((5-(4-fluorophenyl)-2-methyl-4-thiazolyl)carbonyl)-2-piperidinyl)methyl)-4-benzofurancarboxamide 1Melatonin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Sleep Wake Disorders × Clear all
NCT01906866 2024-04-23

Efficacy and Safety of CircadinĀ® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities

Neurim Pharmaceuticals Ltd.

Phase 3 Completed
125 enrolled 22 charts

Autism Spectrum Disorder, Sleep Wake Disorders, Tuberous Sclerosis, Angelman Syndrome, Parasomnias, Smith-Magenis Syndrome

NCT01030939 2017-06-20

Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthy-volunteers

GlaxoSmithKline

Phase 1 Completed
72 enrolled
Endocrine

Sleep Wake Disorders, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚔